Thanh Quang Nguyen

Dr. Thanh Quang Nguyen

Institut de Recherche en Infectiologie de Montpellier, Montpellier, Occitanie, France
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
TNThanh Quang Nguyen
Thanh Quang Nguyen
BHBo Eun Heo
Bo Eun Heo
SJSeunghyeon Jeon
Seunghyeon Jeon
AAAnwesha Ash
Anwesha Ash
HLHeehyun Lee
Heehyun Lee
JJJichan Jang
Jichan Jang
Mycobacterium abscessus, a leading cause of severe lung infections in immunocompromised individuals, poses significant challenges for current therapeutic strategies due to resistance mechanisms. Therefore, understanding the intrinsic and acquired antibiotic resistance of M. abscessus is crucial for effective treatment. This review highlights the mechanisms employed by M. abscessus to sustain antibiotic resistance, encompassing not only conventional drugs but also newly discovered drug candidates. This comprehensive analysis aims to identify novel entities capable of overcoming the notorious resistance exhibited by M. abscessus, providing insights for the development of more effective therapeutic interventions.

Verified
Journal Article
Open access
PDF file
TKTaeho Kim
Taeho Kim
BHBui-Thi-Bich Hanh
Bui-Thi-Bich Hanh
BHBoeun Heo
Boeun Heo
TNThanh Quang Nguyen
Thanh Quang Nguyen
YPYujin Park
Yujin Park
JJJichan Jang
Jichan Jang
Mycobacterium abscessus is the one of the most feared bacterial respiratory pathogens in the world. Unfortunately, there are many problems with the current M. abscessus therapies available. These problems include misdiagnoses, high drug resistance, poor long-term treatment outcomes, and high costs. Until now, there have only been a few new compounds or drug formulations which are active against M. abscessus, and these are present in preclinical and clinical development only. With that in mind, new and more powerful anti-M. abscessus medicines need to be discovered and developed. In this study, we conducted an in vitro-dual screen against M. abscessus rough (R) and smooth (S) variants using a Pandemic Response Box and identified epetraborole as a new effective candidate for M. abscessus therapy. For further validation, epetraborole showed significant activity against the growth of the M. abscessus wild-type strain, three subspecies, drug-resistant strains and clinical isolates in vitro, while also inhibiting the growth of M. abscessus that reside in macrophages without cytotoxicity. Furthermore, the in vivo efficacy of epetraborole in the zebrafish infection model was greater than that of tigecycline. Thus, we concluded that epetraborole is a potential anti-M. abscessus candidate in the M. abscessus drug search.

8 December 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
BHBui Thi Bich Hanh
Bui Thi Bich Hanh
TNThanh Quang Nguyen
Thanh Quang Nguyen
YPYujin Park
Yujin Park
BHBo Eun Heo
Bo Eun Heo
SJSeunghyeon Jeon
Seunghyeon Jeon
JJJichan Jang
Jichan Jang
Mycobacterium abscessus is a difficult respiratory pathogen to treat, when compared to other nontuberculus mycobacteria (NTM), due to its drug resistance. In this study, we aimed to find a new clarithromycin partner that potentiated strong, positive, synergy against M. abscessus among current anti-M. abscessus drugs, including omadacycline, amikacin, rifabutin, bedaquiline, and cefoxitine. First, we determined the minimum inhibitory concentrations required of all the drugs tested for M. abscessus subsp. abscessus CIP104536T treatment using a resazurin microplate assay. Next, the best synergistic partner for clarithromycin against M. abscessus was determined using an in vitro checkerboard combination assay. Among the drug combinations evaluated, omadacycline showed the best synergistic effect with clarithromycin, with a fractional inhibitory concentration index of 0.4. This positive effect was also observed against M. abscessus clinical isolates and anti-M. abscessus drug resistant strains. Lastly, this combination was further validated using a M. abscessus infected zebrafish model. In this model, the clarithromycin-omadacyline regimen was found to inhibit the dissemination of M. abscessus, and it significantly extended the lifespan of the M. abscessus infected zebrafish. In summation, the synergy between two anti-M. abscessus compounds, clarithromycin and omadacycline, provides an attractive foundation for a new M. abscessus treatment regimen.

30 August 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
TNThanh Quang Nguyen
Thanh Quang Nguyen
JJJichan Jang
Jichan Jang
Mycobacterium abscessus has been recognised as a dreadful respiratory pathogen among the non-tuberculous mycobacteria (NTM) because of misdiagnosis, prolonged therapy with poor treatment outcomes and a high cost. This pathogen also shows extremely high antimicrobial resistance against current antibiotics, including the anti-tuberculosis agents. Therefore, current chemotherapies require a long curative period and the clinical outcomes are not satisfactory. Thus, there is an urgent need for discovering and developing novel, more effective anti-M. abscessus drugs. In this review, we sum the effectiveness of the current anti-M. abscessus drugs and drug candidates. Furthermore, we describe the shortcomings and difficulties associated with M. abscessus drug discovery and development.

15 June 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
TNThanh Quang Nguyen
Thanh Quang Nguyen
BHBo Eun Heo
Bo Eun Heo
YPYujin Park
Yujin Park
SJSeunghyeon Jeon
Seunghyeon Jeon
ACArunima Choudhary
Arunima Choudhary
JJJichan Jang
Jichan Jang
In this study, we utilized CRISPR interference (CRISPRi) to specifically target the MAB_0055c gene in M. abscessus , a bacterium that causes difficult-to-treat infections. The study found that silencing the gene lead to increased rifabutin and rifalazil susceptibility.

20 December 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
TNThanh Quang Nguyen
Thanh Quang Nguyen
BHBui Thi Bich Hanh
Bui Thi Bich Hanh
SJSeunghyeon Jeon
Seunghyeon Jeon
BHBo Eun Heo
Bo Eun Heo
YPYujin Park
Yujin Park
JJJichan Jang
Jichan Jang
Q203 is a first-in-class drug candidate against Mycobacterium tuberculosis . In its recently completed phase 2 clinical trial, Q203 reduced the number of live M. tuberculosis cells in a dose-dependent manner.